ES2202330T3 - Emulsiones multiples que contienen ciclosporina. - Google Patents
Emulsiones multiples que contienen ciclosporina.Info
- Publication number
- ES2202330T3 ES2202330T3 ES95106655T ES95106655T ES2202330T3 ES 2202330 T3 ES2202330 T3 ES 2202330T3 ES 95106655 T ES95106655 T ES 95106655T ES 95106655 T ES95106655 T ES 95106655T ES 2202330 T3 ES2202330 T3 ES 2202330T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- cyclosporine
- solution
- ethanol
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 48
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 48
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 33
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 32
- 239000000839 emulsion Substances 0.000 title claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000002904 solvent Substances 0.000 claims abstract description 24
- -1 POLYETHYLENE Polymers 0.000 claims abstract description 8
- 150000001733 carboxylic acid esters Chemical class 0.000 claims abstract description 3
- 239000004094 surface-active agent Substances 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 239000004480 active ingredient Substances 0.000 description 25
- 239000002775 capsule Substances 0.000 description 24
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 14
- 229930105110 Cyclosporin A Natural products 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000007903 gelatin capsule Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000004627 regenerated cellulose Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 5
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 5
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 5
- 108010019249 cyclosporin G Proteins 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229940035044 sorbitan monolaurate Drugs 0.000 description 5
- 108010036941 Cyclosporins Proteins 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000010685 fatty oil Substances 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9403328 | 1994-11-21 | ||
| HU9403328A HU215966B (hu) | 1994-11-21 | 1994-11-21 | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2202330T3 true ES2202330T3 (es) | 2004-04-01 |
Family
ID=10985774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95106655T Expired - Lifetime ES2202330T3 (es) | 1994-11-21 | 1995-05-03 | Emulsiones multiples que contienen ciclosporina. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5583105A (OSRAM) |
| EP (1) | EP0712631B1 (OSRAM) |
| KR (1) | KR100377058B1 (OSRAM) |
| AT (2) | ATE245994T1 (OSRAM) |
| CA (1) | CA2145242C (OSRAM) |
| CZ (1) | CZ286686B6 (OSRAM) |
| DE (2) | DE69531389T2 (OSRAM) |
| DK (1) | DK0712631T3 (OSRAM) |
| ES (1) | ES2202330T3 (OSRAM) |
| GB (1) | GB2295546B (OSRAM) |
| HU (1) | HU215966B (OSRAM) |
| IT (1) | IT1281337B1 (OSRAM) |
| PL (1) | PL182716B1 (OSRAM) |
| PT (1) | PT712631E (OSRAM) |
| SI (1) | SI9500350B (OSRAM) |
| SK (1) | SK283045B6 (OSRAM) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696413B2 (en) * | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| DE19521974A1 (de) * | 1995-06-16 | 1996-12-19 | Hexal Pharmaforschung Gmbh | Pharmazeutische Zubereitung mit Cyclosporin A |
| GB2317562B (en) * | 1995-07-20 | 1999-08-18 | Danbiosyst Uk | Lipid vehicle drug delivery composition containing vitamin E |
| US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| NZ280689A (en) * | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| KR19980073479A (ko) * | 1997-03-14 | 1998-11-05 | 한스루돌프하우스, 니콜케르커 | 사이클로스포린-함유 연질캅셀제 |
| RU2185187C2 (ru) * | 1996-06-19 | 2002-07-20 | Новартис Аг | Препарат, содержащий циклоспорин (варианты), и способ его получения |
| KR0183449B1 (ko) * | 1996-06-19 | 1999-05-01 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| EP1017366A4 (en) * | 1996-09-01 | 2006-03-22 | Pharmos Corp | SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES |
| US5891469A (en) * | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| US5798333A (en) * | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB2326337A (en) * | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
| AU1509799A (en) * | 1997-12-05 | 1999-06-28 | Chong Kun Dang Corporation | Pharmaceutical composition containing cyclosporin |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US6028067A (en) * | 1997-12-05 | 2000-02-22 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| CA2313024C (en) * | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| PT1154759E (pt) | 1998-12-30 | 2008-11-20 | Dexcel Ltd | Concentrado dispersível para administração de ciclosporina |
| US6632443B2 (en) | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US6045826A (en) | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US20080070981A1 (en) | 2000-02-23 | 2008-03-20 | Henryk Borowy-Borowski | Water-soluble compositions of bioactive lipophilic compounds |
| GB9912476D0 (en) * | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
| DE19925001A1 (de) * | 1999-05-31 | 2000-12-07 | Pharma Concepts Gmbh & Co Kg | Flüssiges Konzentrat |
| JP2003513019A (ja) * | 1999-09-27 | 2003-04-08 | ソーナス ファーマシューティカルス，インコーポレイテッド | トコール可溶性治療剤の組成物 |
| WO2001037834A1 (en) * | 1999-11-22 | 2001-05-31 | Galephar Pharmaceutical Research, Inc. | Stable acid labile benzimidazole pharmaceutical compositions |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| US7919113B2 (en) * | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
| US20050037073A1 (en) * | 2000-01-13 | 2005-02-17 | Alpharx Inc. | Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof |
| AU1482102A (en) * | 2000-11-14 | 2002-05-27 | Tocovite Pty Ltd | Complexes of phosphate derivatives |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| CA2453823C (en) * | 2001-07-27 | 2010-12-21 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
| US6960563B2 (en) * | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| BRPI0213658A8 (pt) | 2001-10-19 | 2016-12-06 | F Hoffmann La Roche Ltd | Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resíduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isômero ou com z-isômero de análogos de ciclosporina a modificados no resíduo de 1-aminoácido, mistura de (e) e (z)-isômeros, composição, método para a síntese estereoseletiva do z-isômero de isatx247, método para a preparação de aldeído do ciclosporina a |
| JP2005506990A (ja) * | 2001-10-19 | 2005-03-10 | アイソテクニカ インコーポレーテッド | 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート |
| EP1460995B1 (en) * | 2001-12-13 | 2010-11-10 | Vital Health Sciences Pty Ltd. | Transdermal transport of compounds |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| BRPI0406484A (pt) * | 2003-01-17 | 2005-12-06 | Vital Health Sciences Pty Ltd | Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| US20050074469A1 (en) * | 2003-10-03 | 2005-04-07 | Charles Signorino | Stable lipophilic emulsions for acrylic coating and method of making |
| AU2003267747A1 (en) * | 2003-10-14 | 2005-05-05 | Ramesh Varada Bapat | Sterile gelling agents |
| WO2005074881A2 (en) * | 2004-02-06 | 2005-08-18 | Showa Denko K.K. | Method for stabilizing oil-based thickening gel composition |
| AU2005202477B2 (en) * | 2004-03-03 | 2005-12-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
| US20050277584A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
| US20080064760A1 (en) * | 2004-10-29 | 2008-03-13 | Ping Li | Spontaneously Dispersible Pharmaceutical Composition |
| CA2611831C (en) * | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| US20070087962A1 (en) * | 2005-10-17 | 2007-04-19 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20090005348A1 (en) * | 2005-12-23 | 2009-01-01 | Vital Health Sciences Pty Ltd | Compounds Having Cytokine Modulating Properties |
| EP1867323A1 (en) * | 2006-06-13 | 2007-12-19 | Farmatron Ltd. | Pharmaceutical compositions with biological barriers permeation enhancing properties |
| CN102036661B (zh) * | 2008-03-20 | 2016-12-28 | 维尔恩公司 | 维生素衍生物及其用途 |
| EP2268160B1 (en) | 2008-03-20 | 2012-12-05 | Virun, Inc. | Emulsions including a peg-derivative of tocopherol |
| ES2344674B1 (es) * | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | Composicion farmaceutica inyectable de taxanos. |
| WO2011094814A1 (en) | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| EP2563164B1 (en) | 2010-03-23 | 2016-06-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
| AU2011235597B2 (en) | 2010-03-30 | 2015-07-16 | Phosphagenics Limited | Transdermal delivery patch |
| US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
| RU2580470C2 (ru) | 2010-09-07 | 2016-04-10 | ДСМ Ньютришнл Продактс АГ | Пищевые эмульсии |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| WO2013090842A2 (en) * | 2011-12-16 | 2013-06-20 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers |
| WO2013120025A1 (en) | 2012-02-10 | 2013-08-15 | Virun, Inc. | Beverage compositions containing non-polar compounds |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
| US9693574B2 (en) | 2013-08-08 | 2017-07-04 | Virun, Inc. | Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch |
| US10016363B2 (en) | 2014-09-18 | 2018-07-10 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
| US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| MX392823B (es) | 2016-12-21 | 2025-03-24 | Avecho Biotechnology Ltd | Proceso de fosforilaciónde un alcohol complejo |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE295765C (OSRAM) * | ||||
| DE298351C (OSRAM) * | 1915-04-09 | |||
| SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| US5154930A (en) * | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| DE3908047A1 (de) * | 1989-03-13 | 1990-09-20 | Desitin Arzneimittel Gmbh | Hochdisperse pharmazeutische zusammensetzung |
| AU614465B2 (en) * | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| US5234695A (en) * | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
| HU208491B (en) * | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
| GB9208712D0 (en) * | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| DE59310166D1 (de) * | 1992-05-18 | 2001-05-31 | Ciclomulsion Ag | Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung |
| EP1142568A1 (en) * | 1992-09-25 | 2001-10-10 | Novartis AG | Pharmaceutical compositions containing cyclosporins |
| EP0671929A4 (en) * | 1992-10-16 | 1996-09-25 | Smithkline Beecham Corp | COMPOSITIONS. |
| WO1994008605A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Therapeutic microemulsions |
| JP3644543B2 (ja) * | 1993-10-22 | 2005-04-27 | ヘクサル・アーゲー | シクロスポリンＡ及びα−トコフェロールを含有する医薬組成物 |
| US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
-
1994
- 1994-11-21 HU HU9403328A patent/HU215966B/hu not_active IP Right Cessation
-
1995
- 1995-03-21 CA CA002145242A patent/CA2145242C/en not_active Expired - Fee Related
- 1995-03-31 US US08/414,496 patent/US5583105A/en not_active Expired - Lifetime
- 1995-04-25 CZ CZ19951054A patent/CZ286686B6/cs not_active IP Right Cessation
- 1995-04-27 SK SK544-95A patent/SK283045B6/sk not_active IP Right Cessation
- 1995-05-03 AT AT95106655T patent/ATE245994T1/de not_active IP Right Cessation
- 1995-05-03 DK DK95106655T patent/DK0712631T3/da active
- 1995-05-03 PT PT95106655T patent/PT712631E/pt unknown
- 1995-05-03 DE DE69531389T patent/DE69531389T2/de not_active Expired - Fee Related
- 1995-05-03 ES ES95106655T patent/ES2202330T3/es not_active Expired - Lifetime
- 1995-05-03 EP EP95106655A patent/EP0712631B1/en not_active Expired - Lifetime
- 1995-05-08 KR KR1019950011130A patent/KR100377058B1/ko not_active Expired - Fee Related
- 1995-11-13 SI SI9500350A patent/SI9500350B/sl not_active IP Right Cessation
- 1995-11-14 GB GB9523295A patent/GB2295546B/en not_active Expired - Fee Related
- 1995-11-20 PL PL95311430A patent/PL182716B1/pl not_active IP Right Cessation
- 1995-11-20 DE DE19543271A patent/DE19543271B4/de not_active Expired - Fee Related
- 1995-11-21 IT IT95MI002411A patent/IT1281337B1/it active IP Right Grant
- 1995-11-21 AT AT0189395A patent/AT408945B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE19543271A1 (de) | 1996-06-05 |
| DE69531389T2 (de) | 2004-04-15 |
| SI9500350B (sl) | 2005-02-28 |
| CA2145242C (en) | 2001-08-07 |
| GB2295546B (en) | 1998-07-22 |
| IT1281337B1 (it) | 1998-02-18 |
| SK283045B6 (sk) | 2003-02-04 |
| KR960016903A (ko) | 1996-06-17 |
| ITMI952411A1 (it) | 1997-05-21 |
| CA2145242A1 (en) | 1996-05-22 |
| EP0712631A3 (en) | 1996-12-04 |
| AT408945B (de) | 2002-04-25 |
| EP0712631A2 (en) | 1996-05-22 |
| PL182716B1 (pl) | 2002-02-28 |
| GB9523295D0 (en) | 1996-01-17 |
| SK54495A3 (en) | 1997-02-05 |
| DE69531389D1 (de) | 2003-09-04 |
| ATA189395A (de) | 2001-09-15 |
| SI9500350A (en) | 1996-06-30 |
| KR100377058B1 (ko) | 2003-06-11 |
| GB2295546A (en) | 1996-06-05 |
| HU215966B (hu) | 1999-07-28 |
| CZ286686B6 (en) | 2000-06-14 |
| CZ105495A3 (en) | 1996-07-17 |
| HU9403328D0 (en) | 1995-02-28 |
| DE19543271B4 (de) | 2006-05-24 |
| PL311430A1 (en) | 1996-05-27 |
| DK0712631T3 (da) | 2003-10-27 |
| US5583105A (en) | 1996-12-10 |
| PT712631E (pt) | 2003-11-28 |
| ATE245994T1 (de) | 2003-08-15 |
| EP0712631B1 (en) | 2003-07-30 |
| HK1016814A1 (en) | 1999-11-05 |
| ITMI952411A0 (OSRAM) | 1995-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2202330T3 (es) | Emulsiones multiples que contienen ciclosporina. | |
| US5639474A (en) | Cyclosporin soft capsule composition | |
| US5589455A (en) | Cyclosporin-containing soft capsule compositions | |
| ES2330625T3 (es) | Preconcentrados de microemulsion de analogos de ciclosporina novedosos. | |
| JP2662183B2 (ja) | サイクロスポリン軟質カプセル剤組成物 | |
| EP0711550B1 (en) | Cyclosporin-containing soft capsule compositions | |
| ES2316150T3 (es) | Pre-concentrado de microemulsion que comprende una macrolida. | |
| RU2278657C2 (ru) | Предконцентрат микроэмульсии | |
| ES2239605T3 (es) | Composiciones de ciclosporina substancialmente libres de aceites. | |
| PT91731B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo ciclosporinas | |
| EP0813876B1 (en) | Cyclosporin-containing soft capsule preparations | |
| US5958876A (en) | Cyclosporin-containing pharmaceutical compositions | |
| ES2227700T3 (es) | Preparados de capsulas blandas que contienen ciclosporina. | |
| RU2185188C2 (ru) | Фармацевтические композиции | |
| KR100524700B1 (ko) | 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물 | |
| KR20040074504A (ko) | 사이클로스포린 함유 연질캅셀제 및 그 제조방법 | |
| KR19990047897A (ko) | 사이클로스포린 함유 약학적 조성물 | |
| KR20060086489A (ko) | 사이클로스포린-함유 연질캅셀제 | |
| HK1006780B (en) | Cyclosporin-containing soft capsule preparations |